From the Research
I strongly advise against using domperidone with VELASOF or SOVIHEP V (sofosbuvir/velpatasvir combinations) due to potential drug interactions that can increase the risk of serious cardiac side effects. The provided evidence does not directly address the interaction between domperidone and sofosbuvir/velpatasvir combinations. However, based on the general principles of pharmacology, it is known that sofosbuvir and velpatasvir can inhibit P-glycoprotein (P-gp) transporters in the body, which can lead to increased blood levels of P-gp substrates like domperidone 1, 2, 3, 4, 5.
Potential Risks
- Increased domperidone blood levels can lead to serious cardiac side effects, including QT prolongation and arrhythmias.
- The interaction occurs because sofosbuvir/velpatasvir combinations can block the transport proteins that normally help eliminate domperidone from the body, causing it to accumulate to potentially dangerous levels.
Safer Alternatives
- If an antiemetic is needed while on VELASOF or SOVIHEP V therapy, consider safer alternatives like ondansetron or metoclopramide after consulting with your healthcare provider.
- Always inform your healthcare provider about all medications you are taking before starting hepatitis C treatment to avoid harmful drug interactions.
Key Considerations
- The most recent and highest quality study on sofosbuvir/velpatasvir combinations is from 2022, which highlights the efficacy and safety of this treatment regimen in patients with chronic hepatitis C virus infection 3.
- While the provided evidence does not directly address the interaction between domperidone and sofosbuvir/velpatasvir combinations, the general principles of pharmacology suggest that this interaction can occur.
- As a precautionary measure, it is recommended to avoid using domperidone with VELASOF or SOVIHEP V (sofosbuvir/velpatasvir combinations) to minimize the risk of serious cardiac side effects.